What is Innoviva, Inc.'s durlobactam — royalty expense?

Innoviva, Inc. (INVA) reported durlobactam — royalty expense of $0 in Q2 2026.

What does durlobactam — royalty expense mean?

This metric captures the costs incurred for the right to use intellectual property or licensed technology associated with the production or sale of a specific product segment. It represents the ongoing financial obligation paid to third-party licensors based on the commercial performance of the underlying asset. Monitoring this expense is essential for evaluating the net profitability and margin structure of the segment.

Innoviva, Inc. (INVA) Durlobactam — Royalty Expense

Screener

Other product segments

Giapreza

$1.4M+27.3%

Similar metrics at other companies

KURAKOMZIFTI — Royalty Expense

$25K—

ROADRoyalty Expense

$800K0.0%

IDRGolden Chest — Royalty Expense

$203.11K+59.2%

EGYCanada — Royalty Expense

$437K-67.8%

EGYEgypt — Royalty Expense

$27.31M+15.8%

VNCEVince Wholesale — Royalty Expense

$1.84M+4.2%

Other financials

Income statement

See full

Revenue$119.6M+19.3%

Gross profit$90.6M+9.0%

Operating income$50.9M+4.3%

Net income-$83.4M-231%

EPS (diluted)-$1.14-248%

Balance sheet

See full

Cash & equivalents$570.4M+43.5%

Total debt$269.7M-40.2%

Total equity$1.2B—

Total assets$1.7B+27.7%

Cash flow

See full

Operating cash flow$52.0M+17.9%

CapEx$429.0K—

Free cash flow$51.5M+16.9%

Valuation

See full

Market cap$1.53B+33.1%

Enterprise value$1.22B+2.1%

P/E4.3×-25.4×

P/S3.5×+0.4×

Profitability

See full

Gross margin72.2%-10.9pp

Operating margin36.9%-10.7pp

Net margin81.2%+70.8pp

FCF margin43.1%-11.1pp

Returns & leverage

See full

Return on equity29.1%—

Debt / equity0.2×—

Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RoyaltyExpense.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed: Aug 5, 2026, 4:26 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-335235

The royalty expense in respect of durlobactam arising from our net product sales of XACDURO® was not material during the periods presented.

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s durlobactam — royalty expense?: Innoviva, Inc. (INVA) reported durlobactam — royalty expense of $0 in Q2 2026.
What does durlobactam — royalty expense mean?: This metric captures the costs incurred for the right to use intellectual property or licensed technology associated with the production or sale of a specific product segment. It represents the ongoing financial obligation paid to third-party licensors based on the commercial performance of the underlying asset. Monitoring this expense is essential for evaluating the net profitability and margin structure of the segment.